Among the highlights of UK Chancellor John Healey's first Budget was more than £1 billion in investment by Convatec, Vertex ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

FDA advisors have voted that Capricor Therapeutics has not provided strong evidence of efficacy for its cell therapy for muscle problems associated with Duchenne muscular dystrophy, putting its ...

Shares in GSK fell today on a 2% decline in vaccine sales in the third quarter, although demand for other medicines was ...

Eli Lilly has added another arrow to the quiver of its new diabetes and weight-loss therapy retatrutide, comprehensively ...

AbbVie has filed for FDA approval of its T-cell engager (TCE) etentamig in relapsed or refractory multiple myeloma, a key ...

Sweden's Egetis Therapeutics has launched the first-ever treatment for people living with the ultra-rare genetic disease MCT8 ...

There is a moment, somewhere in a pharma content workflow, when a draft stops being a draft and becomes an action – sent, ...

Bayer's oral Factor XIa inhibitor asundexian has been approved in its first market, China, for secondary stroke prevention, beating its main rival therapy from Bristol Myers Squibb and Johnson & ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad, the main asset in the deal. The oral, once-daily URAT1 ...

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to improve ...

Global chipmaker giant NVIDIA kicked off JPM Week with several partnership announcements, most notably a billion dollar partnership with Indianapolis-based Eli Lilly. "Biology is on the verge of its ...